Filipp V. Gorkavenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Filipp V. Gorkavenko has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Vitaliy Vladimirovich Omelyanovskiy
Center for Healthcare Quality Assessment and Control; Russian Medical Academy of Continuing Professional Education
14 shared publications - Анна Владимировна Никитина
Center for Healthcare Quality Assessment and Control
4 shared publications - D. V. Fedyaev
Center for Healthcare Quality Assessment and Control; Russian Medical Academy of Continuing Professional Education; Financial Research Institute
3 shared publications - D. Yu. Morozov
Center for Expertise and Quality Control of Medical Care
3 shared publications - Maria V. Budzinskaya
Krasnov Research Institute of Eye Diseases
3 shared publications - Anna A. Plyukhova
Krasnov Research Institute of Eye Diseases
2 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Publishing House OKI in Real-World Data & Evidence
- p. 5-15
Resolution of the VII Annual International Scientific and Practical Conference «RWD/RWE. Possible and Real», 2026
The paper presents the resolution of the VII Annual Scientific and Practical Conference with International Participation “Real Clinical Practice. Possible and Real” (Moscow, September 24, 2026), organized by leading professional associations. The document summarizes discussions on the implementation of real-world data and real-world evidence (RWD/RWE) in Russia and the EAEU. It systematizes regulatory and legal barriers in medicinal product regulation, health technology assessment, clinical guideline development, innovative drug provision models, healthcare information systems and registries, and personal data protection and processing. Proposals are formulated to improve legislation, including clarification of the concepts of de-identification and anonymization, broader access to de-identified data, consideration of RWD/RWE in comprehensive drug assessment and list formation, development of interoperability and health data exchange standards (HL7 FHIR), and harmonization at the EAEU level. The resolution also highlights interagency and expert collaboration and the involvement of patient communities.
- 9 November 2026
- Published by Publishing House OKI in Real-World Data & Evidence
- p. 5-15
Open AccessResolution of the VII Annual International Scientific and Practical Conference «RWD/RWE. Possible and Real», 2026
The paper presents the resolution of the VII Annual Scientific and Practical Conference with International Participation “Real Clinical Practice. Possible and Real” (Moscow, September 24, 2026), organized by leading professional associations. The document summarizes discussions on the implementation of real-world data and real-world evidence (RWD/RWE) in Russia and the EAEU. It systematizes regulatory and legal barriers in medicinal product regulation, health technology assessment, clinical guideline development, innovative drug provision models, healthcare information systems and registries, and personal data protection and processing. Proposals are formulated to improve legislation, including clarification of the concepts of de-identification and anonymization, broader access to de-identified data, consideration of RWD/RWE in comprehensive drug assessment and list formation, development of interoperability and health data exchange standards (HL7 FHIR), and harmonization at the EAEU level. The resolution also highlights interagency and expert collaboration and the involvement of patient communities.
- 24 June 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 19 (2) , 334-351
Use of real‑world evidence in comprehensive drug assessment
Background. The rapid development of digital technologies and the increasing recognition of real‑world evidence (RWE) underscore the need for its broader integration in comprehensive drug assessment, including the development of national restrictive lists of drugs). In this context, an analysis of the availability of local (Russian) real‑world studies (RWS) and their use in comprehensive drug assessment is highly relevant. Objective: To analyze the availability of RWE and the frequency of its use in comprehensive drug assessment. Material and methods. The availability of RWS was assessed for 172 drug proposals for inclusion in national restrictive lists between 2020 and 2024. The study was conducted by calculating the proportion of proposals, for which publications reporting the results of local RWS were available at the time of submission. RWS were identified through a systematic search. The frequency of RWE use in comprehensive drug assessment was evaluated through a content analysis of 28 drug dossiers submitted for inclusion in 2022. The frequency of RWE use was also determined in published cost-effectiveness analyses (CEAs) and budget impact analyses (BIAs) of drugs proposed for inclusion in 2018–2024 (116 publications). Results. Over the period from 2020 to 2024, local RWS were published for 34% of drugs proposed for inclusion in the national restrictive lists. In 2022, 86% of drug dossiers included RWS. Among the published CEAs and BIAs submitted in 2018–2024, RWE was used in 42% and 63% of cases, respectively. Conclusions. Russian RWS can already be regarded as a promising source of evidence for comprehensive drug assessment. At the same time, the relatively low publication rate of local RWS indicates the need to further accelerate the generation of such evidence. The high demand for RWE in comprehensive drug assessment underscores the importance of its integration in the development of national restrictive drug lists.
- 24 June 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 19 (2) , 334-351
Use of real‑world evidence in comprehensive drug assessment
Background. The rapid development of digital technologies and the increasing recognition of real‑world evidence (RWE) underscore the need for its broader integration in comprehensive drug assessment, including the development of national restrictive lists of drugs). In this context, an analysis of the availability of local (Russian) real‑world studies (RWS) and their use in comprehensive drug assessment is highly relevant. Objective: To analyze the availability of RWE and the frequency of its use in comprehensive drug assessment. Material and methods. The availability of RWS was assessed for 172 drug proposals for inclusion in national restrictive lists between 2020 and 2024. The study was conducted by calculating the proportion of proposals, for which publications reporting the results of local RWS were available at the time of submission. RWS were identified through a systematic search. The frequency of RWE use in comprehensive drug assessment was evaluated through a content analysis of 28 drug dossiers submitted for inclusion in 2022. The frequency of RWE use was also determined in published cost-effectiveness analyses (CEAs) and budget impact analyses (BIAs) of drugs proposed for inclusion in 2018–2024 (116 publications). Results. Over the period from 2020 to 2024, local RWS were published for 34% of drugs proposed for inclusion in the national restrictive lists. In 2022, 86% of drug dossiers included RWS. Among the published CEAs and BIAs submitted in 2018–2024, RWE was used in 42% and 63% of cases, respectively. Conclusions. Russian RWS can already be regarded as a promising source of evidence for comprehensive drug assessment. At the same time, the relatively low publication rate of local RWS indicates the need to further accelerate the generation of such evidence. The high demand for RWE in comprehensive drug assessment underscores the importance of its integration in the development of national restrictive drug lists.
- 6 April 2026
- Published by Publishing House OKI in Real-World Data & Evidence
- Vol. 6 (1) , 60-70
The place of real-world evidence in conducting clinical and economic analysis
Relevance. Real-world evidence (RWE) can be widely used in cost-effectiveness analysis (CEA) and budget impact analysis (BIA) conducted to justify the inclusion of new medicines in restrictive drug lists. However, researches of RWE use experience in drug assessment in the Russian Federation is currently limited, which makes it necessary to conduct such a research. Our goal is to analyze of the practice of using RWE in preparation of dossiers, conducting CEA and BIA for drugs proposed for inclusion in the restrictive drug lists in the Russian Federation. Materials and methods. The practice of using RWE in a drug assessment was studied through a content analysis of 28 proposals for the inclusion of drugs in restrictive lists (vital and essential drugs list, high-cost nosology list) in 2022, published CEA (n=109) and BIA (n=82) which were used for drug inclusion in 2018–2024. Results. In the dossier, real-world studies were used primarily for descriptive purposes, to characterize the proposed drug, current treatment practice, and the therapeutic area. In published CEAs RWE was most often used to increase the completeness of costs taken into account (34 % of uses), increase the accuracy of cost calculations (24 %), and take effectiveness into account when calculating the cost-effectiveness ratios (19 %). In the BIA RWE was most often used to calculate the target patient population (51 % of evidence uses), increase the accuracy of cost calculations (22 %), and more fully account for costs (18 %). RWE characterized the proposed drug and/or comparator in only 44 % of cases in CEAs and 22 % in BIAs; in the remaining cases, it described patients, characteristics of medical care, or the use of medical interventions after or as a result of the use of the compared medicinal products. The use of RWE from other countries is prevalent in CEAs (62 % of uses) and accounts for a significant share in the BIAs (31 % of uses). Conclusions. In drug assessment RWE is used for a wide range of purposes and characterizes a wide range of parameters for the drugs under scope, target patient groups, treatment patterns, and the long-term outcomes of using the drug. The identified specific features of the RWE use practice differ from expectations, according to which its use should be focused primarily on the compared drugs and describe their effectiveness and safety. It was shown that RWE most often did not describe compared drugs and did not address their efficacy and safety. The significant share of non-local RWE necessitatesthe development of measures aimed at increasing the volume of local RWE.
- 6 April 2026
- Published by Publishing House OKI in Real-World Data & Evidence
- Vol. 6 (1) , 60-70
The place of real-world evidence in conducting clinical and economic analysis
Relevance. Real-world evidence (RWE) can be widely used in cost-effectiveness analysis (CEA) and budget impact analysis (BIA) conducted to justify the inclusion of new medicines in restrictive drug lists. However, researches of RWE use experience in drug assessment in the Russian Federation is currently limited, which makes it necessary to conduct such a research. Our goal is to analyze of the practice of using RWE in preparation of dossiers, conducting CEA and BIA for drugs proposed for inclusion in the restrictive drug lists in the Russian Federation. Materials and methods. The practice of using RWE in a drug assessment was studied through a content analysis of 28 proposals for the inclusion of drugs in restrictive lists (vital and essential drugs list, high-cost nosology list) in 2022, published CEA (n=109) and BIA (n=82) which were used for drug inclusion in 2018–2024. Results. In the dossier, real-world studies were used primarily for descriptive purposes, to characterize the proposed drug, current treatment practice, and the therapeutic area. In published CEAs RWE was most often used to increase the completeness of costs taken into account (34 % of uses), increase the accuracy of cost calculations (24 %), and take effectiveness into account when calculating the cost-effectiveness ratios (19 %). In the BIA RWE was most often used to calculate the target patient population (51 % of evidence uses), increase the accuracy of cost calculations (22 %), and more fully account for costs (18 %). RWE characterized the proposed drug and/or comparator in only 44 % of cases in CEAs and 22 % in BIAs; in the remaining cases, it described patients, characteristics of medical care, or the use of medical interventions after or as a result of the use of the compared medicinal products. The use of RWE from other countries is prevalent in CEAs (62 % of uses) and accounts for a significant share in the BIAs (31 % of uses). Conclusions. In drug assessment RWE is used for a wide range of purposes and characterizes a wide range of parameters for the drugs under scope, target patient groups, treatment patterns, and the long-term outcomes of using the drug. The identified specific features of the RWE use practice differ from expectations, according to which its use should be focused primarily on the compared drugs and describe their effectiveness and safety. It was shown that RWE most often did not describe compared drugs and did not address their efficacy and safety. The significant share of non-local RWE necessitatesthe development of measures aimed at increasing the volume of local RWE.
- 22 January 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (4) , 473-482
Basic approaches to assessment of digital health products and services in the Russian Federation
Objective: To analyze the applicability of approaches conventionally used to assess the clinical and economic effectiveness of pharmaceuticals to that of digital health products and services (DHPS). Material and methods. In this study, DHPS was considered to be an umbrella concept that encompasses various health technologies such as mobile health apps and services, including those based on artificial intelligence. Approaches to drug assessment were reviewed based on regulatory documents, methodological guidelines, and monographs on drugs assessment. Results. The examined approaches to assessing the effectiveness and safety of pharmaceuticals can be applied to DHPS, having no fundamental limitations. Specific characteristics of DHPS that influence the choice of their assessment approaches were identified and described. A draft dossier for DHPS was proposed, with its composition aligned with the goals and objectives of the assessment task. Conclusion. Future research should address the development of methodological guidelines for assessing DHPS based on the approaches used for drug assessment.
- 22 January 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (4) , 473-482
Basic approaches to assessment of digital health products and services in the Russian Federation
Objective: To analyze the applicability of approaches conventionally used to assess the clinical and economic effectiveness of pharmaceuticals to that of digital health products and services (DHPS). Material and methods. In this study, DHPS was considered to be an umbrella concept that encompasses various health technologies such as mobile health apps and services, including those based on artificial intelligence. Approaches to drug assessment were reviewed based on regulatory documents, methodological guidelines, and monographs on drugs assessment. Results. The examined approaches to assessing the effectiveness and safety of pharmaceuticals can be applied to DHPS, having no fundamental limitations. Specific characteristics of DHPS that influence the choice of their assessment approaches were identified and described. A draft dossier for DHPS was proposed, with its composition aligned with the goals and objectives of the assessment task. Conclusion. Future research should address the development of methodological guidelines for assessing DHPS based on the approaches used for drug assessment.
- Open Access
- 28 December 2025
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 22 (4) , 866-875
Prediction of Diabetic Retinopathy Progression Based on Logistic Regression Model
Diabetic retinopathy (DR) remains a leading cause of blindness in the working-age diabetic population. DR progression often occurs asymptomatically, and current screening methods do not always detect the onset of retinal deterioration in a timely manner. This creates a strong need for risk prediction models that can identify high-risk patients in advance and enable prompt preventive treatment. Moreover, the pathogenic mechanisms of DR may differ between type 1 and type 2 diabetes (neurodegeneration and inflammation vs. microangiopathy), which justifies developing separate progression models for each diabetes type. Purpose: tо develop and validate multivariable logistic regression models predicting 1-year progression of diabetic retinopathy (DR) in type 1 diabetes (T1D), type 2 diabetes (T2D), and a combined cohort, and to compare their accuracy and key predictors. Patients and methods. In this prospective study, 731 patients (731 eyes) without proliferative DR underwent optical coherence tomography (OCT), OCT angiography (OCTA), and systemic evaluation. A total of 102 candidate predictors were considered. Separate multivariable logistic models were built for T1D, T2D, and the combined cohort (75 % training / 25 % validation; class balancing). Performance was assessed by macro F-measure, sensitivity, specificity, and negative predictive value (NPV). Results. The T1D model achieved a macro F-score of 0.96 with 100 % sensitivity and 97.3 % specificity (NPV 100 %). The T2D model yielded a macro F-score of 0.85 with 90.5 % sensitivity and 87.8 % specificity (NPV 97 %). The combined model showed a macro F-score of 0.91 with 91.2 % sensitivity and 94.6 % specificity (NPV 97.9 %). Key predictors were: for T1D— hyperreflective foci (HRF), relative ganglion cell complex thickness (GCC %), and central retinal thickness; for T2D—fractal dimension in the superficial capillary plexus (FD-SCP), GCC and GCL+ thicknesses, and estimated glomerular filtration rate (eGFR); for the combined model—HRF, GCC, GCL+, and eGFR. Conclusions. Logistic regression models were developed for T1D, T2D, and a combined cohort; validation confirmed high predictive accuracy and delineated distinct key predictors—predominantly neurodegenerative and neuroinflammatory biomarkers in T1D, and neurodegenerative, vascular, and systemic indicators in T2D.
- 28 December 2025
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 22 (4) , 866-875
Open AccessPrediction of Diabetic Retinopathy Progression Based on Logistic Regression Model
Diabetic retinopathy (DR) remains a leading cause of blindness in the working-age diabetic population. DR progression often occurs asymptomatically, and current screening methods do not always detect the onset of retinal deterioration in a timely manner. This creates a strong need for risk prediction models that can identify high-risk patients in advance and enable prompt preventive treatment. Moreover, the pathogenic mechanisms of DR may differ between type 1 and type 2 diabetes (neurodegeneration and inflammation vs. microangiopathy), which justifies developing separate progression models for each diabetes type. Purpose: tо develop and validate multivariable logistic regression models predicting 1-year progression of diabetic retinopathy (DR) in type 1 diabetes (T1D), type 2 diabetes (T2D), and a combined cohort, and to compare their accuracy and key predictors. Patients and methods. In this prospective study, 731 patients (731 eyes) without proliferative DR underwent optical coherence tomography (OCT), OCT angiography (OCTA), and systemic evaluation. A total of 102 candidate predictors were considered. Separate multivariable logistic models were built for T1D, T2D, and the combined cohort (75 % training / 25 % validation; class balancing). Performance was assessed by macro F-measure, sensitivity, specificity, and negative predictive value (NPV). Results. The T1D model achieved a macro F-score of 0.96 with 100 % sensitivity and 97.3 % specificity (NPV 100 %). The T2D model yielded a macro F-score of 0.85 with 90.5 % sensitivity and 87.8 % specificity (NPV 97 %). The combined model showed a macro F-score of 0.91 with 91.2 % sensitivity and 94.6 % specificity (NPV 97.9 %). Key predictors were: for T1D— hyperreflective foci (HRF), relative ganglion cell complex thickness (GCC %), and central retinal thickness; for T2D—fractal dimension in the superficial capillary plexus (FD-SCP), GCC and GCL+ thicknesses, and estimated glomerular filtration rate (eGFR); for the combined model—HRF, GCC, GCL+, and eGFR. Conclusions. Logistic regression models were developed for T1D, T2D, and a combined cohort; validation confirmed high predictive accuracy and delineated distinct key predictors—predominantly neurodegenerative and neuroinflammatory biomarkers in T1D, and neurodegenerative, vascular, and systemic indicators in T2D.
- Open Access
- 22 October 2025
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (3) , 357-364
Results of the survey of experts on the need to incorporate real-world evidence to the comprehensive drug assessment
Background . Specialists in health technology assessment consider real-world evidence (RWE) a promising path for improving comprehensive drug assessment (CDA). Therefore, it is particularly important to elicit opinions from CDA experts on the necessity of incorporating RWE analysis into the assessment process. Objective : To present the results of a survey of CDA specialists demonstrating their views on the necessity and variability of incorporating RWE into the CDA process. Material and methods . The survey was conducted in the form of a specially developed original questionnaire between July 2024 and February 2025 among two groups: regulatory authority representatives and pharmaceutical industry representatives involved in CDA. Results . The survey involved 29 representatives from both regulatory authorities and pharmaceutical industry. The majority of respondents support the inclusion of RWE in CDA: 96.6% of regulatory authority representatives vs 75.9% of industry representatives. The most favored assessment areas using RWE were safety, efficacy, impact on economy, and the quality of evidence base for medicinal products. The predominant view was that in decision-making, the role of RWE should be informative rather than restrictive. Conclusion . The surveyed respondents specialising in CDA predominantly hold positive attitudes towards incorporating RWE into the assessment procedure. The support of this incorporation by experts implies that work on specific implementations of RWE in CDA is fully justified and promises to be successful.
- 22 October 2025
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (3) , 357-364
Open AccessResults of the survey of experts on the need to incorporate real-world evidence to the comprehensive drug assessment
Background . Specialists in health technology assessment consider real-world evidence (RWE) a promising path for improving comprehensive drug assessment (CDA). Therefore, it is particularly important to elicit opinions from CDA experts on the necessity of incorporating RWE analysis into the assessment process. Objective : To present the results of a survey of CDA specialists demonstrating their views on the necessity and variability of incorporating RWE into the CDA process. Material and methods . The survey was conducted in the form of a specially developed original questionnaire between July 2024 and February 2025 among two groups: regulatory authority representatives and pharmaceutical industry representatives involved in CDA. Results . The survey involved 29 representatives from both regulatory authorities and pharmaceutical industry. The majority of respondents support the inclusion of RWE in CDA: 96.6% of regulatory authority representatives vs 75.9% of industry representatives. The most favored assessment areas using RWE were safety, efficacy, impact on economy, and the quality of evidence base for medicinal products. The predominant view was that in decision-making, the role of RWE should be informative rather than restrictive. Conclusion . The surveyed respondents specialising in CDA predominantly hold positive attitudes towards incorporating RWE into the assessment procedure. The support of this incorporation by experts implies that work on specific implementations of RWE in CDA is fully justified and promises to be successful.
- Open Access
- 22 October 2025
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (3) , 309-319
Modeling the efficiency of chronic hepatitis С treatment
Objective : To explore approaches to improving medical care for patients with chronic hepatitis С (CHC) at the national level. Material and methods. A Markov model was used to predict the direct medical costs and outcomes (e.g., number of cured and died patients, cases of complications) for the treatment of CHC for 6 years in 300,000 patients. Two modeling scenarios were considered: a basic scenario included therapy administered with drugs in accordance with clinical guidelines and the standard of medical care for CHC patients; an alternative scenario focused on therapy with pan-genotypic drugs only. Results . In the basic scenario, 298,034 people, or 99.3% of the cohort are treated over a period of 6 years. During this time, the disease develops into 236 cases of decompensated liver cirrhosis, 2,073 cases of hepatocellular carcinoma, 62 liver transplants required, and 430 deaths from complications of progressive liver decompensation. Total direct medical costs for this period are estimated at 105.3 billion rubles. Annual costs range from 16.5 billion rubles in the first year to 18.2 billion rubles in the sixth year. In the alternative scenario, a slight improvement in clinical outcomes is observed; however, the treatment cost increases from 105.8 billion rubles to 114.5 billion rubles (+8.7 billion rubles). It was found that decrease in the cost of drugs by 10%, 20%, 30%, or 40% can provide additional treatment for 31,706, 70,907, 120,615, and 185,707 patients, respectively. Conclusion . The study made possible to assess the efficiency of the proposed measures for treating patients with CHC over a 6-year horizon, as well as the financial requirements for their implementation. Furthermore, possible measures to improve the effectiveness of CHC control activities and prospective ways to realize the benefits that could be achieved by reducing the cost of drug therapy were considered.
- 22 October 2025
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (3) , 309-319
Open AccessModeling the efficiency of chronic hepatitis С treatment
Objective : To explore approaches to improving medical care for patients with chronic hepatitis С (CHC) at the national level. Material and methods. A Markov model was used to predict the direct medical costs and outcomes (e.g., number of cured and died patients, cases of complications) for the treatment of CHC for 6 years in 300,000 patients. Two modeling scenarios were considered: a basic scenario included therapy administered with drugs in accordance with clinical guidelines and the standard of medical care for CHC patients; an alternative scenario focused on therapy with pan-genotypic drugs only. Results . In the basic scenario, 298,034 people, or 99.3% of the cohort are treated over a period of 6 years. During this time, the disease develops into 236 cases of decompensated liver cirrhosis, 2,073 cases of hepatocellular carcinoma, 62 liver transplants required, and 430 deaths from complications of progressive liver decompensation. Total direct medical costs for this period are estimated at 105.3 billion rubles. Annual costs range from 16.5 billion rubles in the first year to 18.2 billion rubles in the sixth year. In the alternative scenario, a slight improvement in clinical outcomes is observed; however, the treatment cost increases from 105.8 billion rubles to 114.5 billion rubles (+8.7 billion rubles). It was found that decrease in the cost of drugs by 10%, 20%, 30%, or 40% can provide additional treatment for 31,706, 70,907, 120,615, and 185,707 patients, respectively. Conclusion . The study made possible to assess the efficiency of the proposed measures for treating patients with CHC over a 6-year horizon, as well as the financial requirements for their implementation. Furthermore, possible measures to improve the effectiveness of CHC control activities and prospective ways to realize the benefits that could be achieved by reducing the cost of drug therapy were considered.
- Open Access
- 11 September 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (4)
Endpoints and Outcomes in Real-World Oncology Clinical Trials
В статье акцентируется внимание на значении конечных точек как ключевого критерия надежности результатов в исследованиях реальной клинической практики (РКП), а также в клинических исследованиях в целом. Представлена актуальная классификация конечных точек (исходов) в контексте онкологических исследований, включая определения, особенности, преимущества и недостатки. Особое внимание уделено тому, как конечные точки могут быть адаптированы для использования в исследованиях РКП, чтобы обеспечить более точное и достоверное отражение клинической реальности. В практических целях перечислены виды данных (атрибутный состав), необходимых для полноценной оценки каждого из исходов. В статье речь идет о таких общепринятых для онкологических исследований конечных точках с анализом времени до наступления события, как общая выживаемость, выживаемость без прогрессирования, безрецидивная выживаемость. Также подробно рассмотрены возможности использования дополнительных и альтернативных конечных точек, таких как опухоль-специфическая выживаемость, время до неудачи или прекращения лечения и ряд других исходов.
- 11 September 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (4)
Open AccessEndpoints and Outcomes in Real-World Oncology Clinical Trials
В статье акцентируется внимание на значении конечных точек как ключевого критерия надежности результатов в исследованиях реальной клинической практики (РКП), а также в клинических исследованиях в целом. Представлена актуальная классификация конечных точек (исходов) в контексте онкологических исследований, включая определения, особенности, преимущества и недостатки. Особое внимание уделено тому, как конечные точки могут быть адаптированы для использования в исследованиях РКП, чтобы обеспечить более точное и достоверное отражение клинической реальности. В практических целях перечислены виды данных (атрибутный состав), необходимых для полноценной оценки каждого из исходов. В статье речь идет о таких общепринятых для онкологических исследований конечных точках с анализом времени до наступления события, как общая выживаемость, выживаемость без прогрессирования, безрецидивная выживаемость. Также подробно рассмотрены возможности использования дополнительных и альтернативных конечных точек, таких как опухоль-специфическая выживаемость, время до неудачи или прекращения лечения и ряд других исходов.
- 9 September 2025
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 47 (3)
The Webiomed.DHRA decision-making support system for medical examinations in the Russian Federation: a cost-effectiveness analysis
Objective. Cost-effectiveness analysis of decision-making support system with artificial intelligence automating risk assessment using the SCORE scale in preventive medical examinations. Material and methods. An original mathematical model was created to simulate 10-year survival of patients with various cardiovascular risks assessed by the SCORE system. Two scenarios were compared: (1) risk assessment by a physician with decision-making support system, and (2) risk assessment without decision-making support. The primary effectiveness outcome was life-years gained per a patient. The incremental cost-effectiveness ratio (ICER) was calculated to assess economic feasibility. Analysis was conducted from the healthcare system perspective. We considered the following costs: implementation of decision-making support system, physician visits (screening, diagnosis, treatment assignment, follow-up), and pharmacotherapy for patients entitled to medication benefits. The target population was adults aged 40—65 without CVD, type 2 diabetes mellitus, or chronic kidney disease. Clinical efficacy in the model corresponded to efficacy of the Webiomed.DHRA decision-making support system that was expressed in accuracy of determining the CVR (“correctness”) according to the SCORE scale. Results. The modeled 10-year mortality was 1.25% in scenario 1 and 3.70% in scenario 2 (OR 0.33, 95% CI: 0.27—0.40). Thus, there was significantly lower mortality in case of decision-making support system. Mean undiscounted annual cost per patient was RUB 7.947.97 (discounted: RUB 6.530) and RUB 4.444 (discounted: RUB 3.683), respectively. The ICER was RUB 276.905 per life-year gained without discounting and RUB 224.983 with discounting. This value is lower than cost-effectiveness threshold for 2024. The majority of costs (87.61%) were attributed to medical visits, while implementation of decision-making support system accounted for only 0.051%. Conclusion. Introduction of decision-making support system with artificial intelligence for assessing cardiovascular risks into regional healthcare system will reduce mortality over the next 10 years after medical examination. According to cost-effectiveness analysis, this system is economically acceptable medical technology.
- 9 September 2025
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 47 (3)
The Webiomed.DHRA decision-making support system for medical examinations in the Russian Federation: a cost-effectiveness analysis
Objective. Cost-effectiveness analysis of decision-making support system with artificial intelligence automating risk assessment using the SCORE scale in preventive medical examinations. Material and methods. An original mathematical model was created to simulate 10-year survival of patients with various cardiovascular risks assessed by the SCORE system. Two scenarios were compared: (1) risk assessment by a physician with decision-making support system, and (2) risk assessment without decision-making support. The primary effectiveness outcome was life-years gained per a patient. The incremental cost-effectiveness ratio (ICER) was calculated to assess economic feasibility. Analysis was conducted from the healthcare system perspective. We considered the following costs: implementation of decision-making support system, physician visits (screening, diagnosis, treatment assignment, follow-up), and pharmacotherapy for patients entitled to medication benefits. The target population was adults aged 40—65 without CVD, type 2 diabetes mellitus, or chronic kidney disease. Clinical efficacy in the model corresponded to efficacy of the Webiomed.DHRA decision-making support system that was expressed in accuracy of determining the CVR (“correctness”) according to the SCORE scale. Results. The modeled 10-year mortality was 1.25% in scenario 1 and 3.70% in scenario 2 (OR 0.33, 95% CI: 0.27—0.40). Thus, there was significantly lower mortality in case of decision-making support system. Mean undiscounted annual cost per patient was RUB 7.947.97 (discounted: RUB 6.530) and RUB 4.444 (discounted: RUB 3.683), respectively. The ICER was RUB 276.905 per life-year gained without discounting and RUB 224.983 with discounting. This value is lower than cost-effectiveness threshold for 2024. The majority of costs (87.61%) were attributed to medical visits, while implementation of decision-making support system accounted for only 0.051%. Conclusion. Introduction of decision-making support system with artificial intelligence for assessing cardiovascular risks into regional healthcare system will reduce mortality over the next 10 years after medical examination. According to cost-effectiveness analysis, this system is economically acceptable medical technology.
- Open Access
- 6 August 2025
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (2) , 184-198
Marketing analysis of the Russian pharmaceutical market for treatment of neovascular age-related macular degeneration
Background. Studies on the pharmaceutical provision of neovascular age-related macular degeneration with angiogenesis inhibitors in the Russian Federation have repeatedly indicated a mismatch between the level of consumption and the actual need for these drugs. This highlights the importance of further research on the issue through marketing analysis.Objective: To conduct a marketing analysis of the market for angiogenesis inhibitors used in the treatment of neovascular age-related macular degeneration, including assessment of the product range, price dynamics, demand and consumption, as well as index analysis for the period of 2018–2024.Material and methods. The study was based on open data on the procurement of angiogenesis inhibitors in the public sector, price characteristics, and information on consumption with compulsory health insurance system (24-hour and day hospitals as well as high-tech medical care). The scientific and methodological framework of the study included methods for analyzing the sales of drugs from the group of angiogenesis inhibitors registered for medical use in the Russian Federation, as well as methodological tools for calculating a series of chain indices (including the weighted average price index, price index, structural shift index, index of changes in sales volumes in physical terms, modified Herfindahl–Hirschman index). Methods for analyzing the life cycle of the drugs and comparing the volumes of their procurement and consumption volumes were also used.Results. During the study period, there was a noticeable increase in the demand for and consumption of angiogenesis inhibitors: procurement volumes in physical terms grew 2.53-fold, and in monetary terms 1.62-fold. The positive dynamics of the market for the studied group of drugs were accompanied by an increase in weighted average prices and a growing share of more expensive drugs in the procurement structure. Between 2021 and 2023, uneven growth was observed in procurement volumes in physical terms and in the number of hospitalizations involving the use of these drugs. The ratio of hospitalization volumes to procurement volumes during this period was 1.21, 1.46, and 1.47, respectively, indicating that a single vial of the drug was used for multiple patients. The disproportion between procurement volumes and the number of hospitalizations points to a significant additional potential demand for angiogenesis inhibitors. The current market conditions can be characterized as attractive for manufacturers and suppliers.Conclusion. It was established that the market for angiogenesis inhibitors was characterized by both qualitative and quantitative growth, with sustained positive development dynamics. The identified features of procurement and consumption indicate the need for further research aimed at developing optimal solutions for ensuring the pharmaceutical provision of angiogenesis inhibitors to consumers in the required range and sufficient volumes.
- 6 August 2025
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (2) , 184-198
Open AccessMarketing analysis of the Russian pharmaceutical market for treatment of neovascular age-related macular degeneration
Background. Studies on the pharmaceutical provision of neovascular age-related macular degeneration with angiogenesis inhibitors in the Russian Federation have repeatedly indicated a mismatch between the level of consumption and the actual need for these drugs. This highlights the importance of further research on the issue through marketing analysis.Objective: To conduct a marketing analysis of the market for angiogenesis inhibitors used in the treatment of neovascular age-related macular degeneration, including assessment of the product range, price dynamics, demand and consumption, as well as index analysis for the period of 2018–2024.Material and methods. The study was based on open data on the procurement of angiogenesis inhibitors in the public sector, price characteristics, and information on consumption with compulsory health insurance system (24-hour and day hospitals as well as high-tech medical care). The scientific and methodological framework of the study included methods for analyzing the sales of drugs from the group of angiogenesis inhibitors registered for medical use in the Russian Federation, as well as methodological tools for calculating a series of chain indices (including the weighted average price index, price index, structural shift index, index of changes in sales volumes in physical terms, modified Herfindahl–Hirschman index). Methods for analyzing the life cycle of the drugs and comparing the volumes of their procurement and consumption volumes were also used.Results. During the study period, there was a noticeable increase in the demand for and consumption of angiogenesis inhibitors: procurement volumes in physical terms grew 2.53-fold, and in monetary terms 1.62-fold. The positive dynamics of the market for the studied group of drugs were accompanied by an increase in weighted average prices and a growing share of more expensive drugs in the procurement structure. Between 2021 and 2023, uneven growth was observed in procurement volumes in physical terms and in the number of hospitalizations involving the use of these drugs. The ratio of hospitalization volumes to procurement volumes during this period was 1.21, 1.46, and 1.47, respectively, indicating that a single vial of the drug was used for multiple patients. The disproportion between procurement volumes and the number of hospitalizations points to a significant additional potential demand for angiogenesis inhibitors. The current market conditions can be characterized as attractive for manufacturers and suppliers.Conclusion. It was established that the market for angiogenesis inhibitors was characterized by both qualitative and quantitative growth, with sustained positive development dynamics. The identified features of procurement and consumption indicate the need for further research aimed at developing optimal solutions for ensuring the pharmaceutical provision of angiogenesis inhibitors to consumers in the required range and sufficient volumes.